Strata Skin Sciences (NASDAQ:SSKN) Rating Increased to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Strata Skin Sciences (NASDAQ:SSKN) from a sell rating to a hold rating in a research report released on Saturday morning.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Strata Skin Sciences in a research report on Wednesday, October 8th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $6.00.

Strata Skin Sciences Trading Down 4.6%

SSKN stock opened at $1.25 on Friday. Strata Skin Sciences has a twelve month low of $1.24 and a twelve month high of $3.86. The stock has a market capitalization of $7.36 million, a price-to-earnings ratio of -0.44 and a beta of 0.48. The company has a quick ratio of 0.75, a current ratio of 0.98 and a debt-to-equity ratio of 49.58. The firm’s fifty day simple moving average is $1.76 and its two-hundred day simple moving average is $2.04.

Strata Skin Sciences (NASDAQ:SSKN) last released its quarterly earnings results on Thursday, November 13th. The medical device company reported ($0.36) EPS for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.12). Strata Skin Sciences had a negative return on equity of 266.94% and a negative net margin of 35.13%.The firm had revenue of $6.93 million for the quarter, compared to analysts’ expectations of $7.72 million. As a group, analysts anticipate that Strata Skin Sciences will post -1.05 earnings per share for the current year.

Institutional Investors Weigh In On Strata Skin Sciences

An institutional investor recently bought a new position in Strata Skin Sciences stock. Susquehanna International Group LLP bought a new stake in Strata Skin Sciences, Inc. (NASDAQ:SSKN) during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund bought 12,426 shares of the medical device company’s stock, valued at approximately $26,000. Susquehanna International Group LLP owned about 0.24% of Strata Skin Sciences at the end of the most recent reporting period. 32.43% of the stock is owned by hedge funds and other institutional investors.

About Strata Skin Sciences

STRATA Skin Sciences, Inc, a medical technology company, develops, commercializes, and markets products for the treatment of dermatologic conditions in the United States, Europe, the Middle East, Asia, Australia, South Africa, and Central and South America. The company operates in two segments, Dermatology Recurring Procedures and Dermatology Procedures Equipment.